^Scheideler MA, Martin J, Hohlweg R, Rasmussen JS, Naerum L, Ludvigsen TS, et al. (November 1997). "The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain". European Journal of Pharmacology. 339 (2–3): 261–70.
doi:
10.1016/S0014-2999(97)01372-1.
PMID9473144.
^Fink-Jensen A, Nielsen EB, Hansen L, Scheideler MA (January 1998). "Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI". European Journal of Pharmacology. 342 (2–3): 153–61.
doi:
10.1016/S0014-2999(97)01494-5.
PMID9548380.
^Malik P, Andersen MB, Peacock L (August 2004). "The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia". Pharmacology, Biochemistry, and Behavior. 78 (4): 805–10.
doi:
10.1016/j.pbb.2004.05.019.
PMID15301939.
S2CID19410897.